Switch theme
Sign up to access all valuation multiples
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
2005
73
LTM Revenue $28.3M
Last FY EBITDA -$45.3M
$19.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Assembly Biosciences has a last 12-month revenue (LTM) of $28.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Assembly Biosciences achieved revenue of $28.5M and an EBITDA of -$45.3M.
Assembly Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Assembly Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.3M | XXX | $28.5M | XXX | XXX | XXX |
| Gross Profit | $28.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$45.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -159% | XXX | XXX | XXX |
| EBIT | -$47.5M | XXX | -$45.4M | XXX | XXX | XXX |
| EBIT Margin | -168% | XXX | -159% | XXX | XXX | XXX |
| Net Profit | -$42.9M | XXX | -$40.2M | XXX | XXX | XXX |
| Net Margin | -152% | XXX | -141% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Assembly Biosciences's stock price is $14.
Assembly Biosciences has current market cap of $107M, and EV of $19.0M.
See Assembly Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.0M | $107M | XXX | XXX | XXX | XXX | $-6.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Assembly Biosciences has market cap of $107M and EV of $19.0M.
Assembly Biosciences's trades at 0.7x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Assembly Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Assembly Biosciences has a P/E ratio of -2.5x.
See valuation multiples for Assembly Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $107M | XXX | $107M | XXX | XXX | XXX |
| EV (current) | $19.0M | XXX | $19.0M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAssembly Biosciences's last 12 month revenue growth is -13%
Assembly Biosciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.0M for the same period.
Assembly Biosciences's rule of 40 is -909% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Assembly Biosciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Assembly Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -13% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -159% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -909% | XXX | -172% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 196% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 259% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assembly Biosciences acquired XXX companies to date.
Last acquisition by Assembly Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Assembly Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Assembly Biosciences founded? | Assembly Biosciences was founded in 2005. |
| Where is Assembly Biosciences headquartered? | Assembly Biosciences is headquartered in United States of America. |
| How many employees does Assembly Biosciences have? | As of today, Assembly Biosciences has 73 employees. |
| Who is the CEO of Assembly Biosciences? | Assembly Biosciences's CEO is Mr. Jason A. Okazaki. |
| Is Assembly Biosciences publicy listed? | Yes, Assembly Biosciences is a public company listed on NAS. |
| What is the stock symbol of Assembly Biosciences? | Assembly Biosciences trades under ASMB ticker. |
| When did Assembly Biosciences go public? | Assembly Biosciences went public in 2010. |
| Who are competitors of Assembly Biosciences? | Similar companies to Assembly Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Assembly Biosciences? | Assembly Biosciences's current market cap is $107M |
| What is the current revenue of Assembly Biosciences? | Assembly Biosciences's last 12 months revenue is $28.3M. |
| What is the current revenue growth of Assembly Biosciences? | Assembly Biosciences revenue growth (NTM/LTM) is -13%. |
| What is the current EV/Revenue multiple of Assembly Biosciences? | Current revenue multiple of Assembly Biosciences is 0.7x. |
| Is Assembly Biosciences profitable? | Yes, Assembly Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
